These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18053714)

  • 1. Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Convery MA; Diallo H; Hortense E; Irving WR; Kelly HA; King NP; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2008 Jan; 18(1):28-33. PubMed ID: 18053714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
    Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ
    Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs.
    Young RJ; Adams C; Blows M; Brown D; Burns-Kurtis CL; Chan C; Chaudry L; Convery MA; Davies DE; Exall AM; Foster G; Harling JD; Hortense E; Irvine S; Irving WR; Jackson S; Kleanthous S; Pateman AJ; Patikis AN; Roethka TJ; Senger S; Stelman GJ; Toomey JR; West RI; Whittaker C; Zhou P; Watson NS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1582-7. PubMed ID: 21349710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
    Zhang P; Zuckett JF; Woolfrey J; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1657-61. PubMed ID: 12039584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.
    Guertin KR; Gardner CJ; Klein SI; Zulli AL; Czekaj M; Gong Y; Spada AP; Cheney DL; Maignan S; Guilloteau JP; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Dunwiddie CT; Leadley RJ; Pauls HW
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1671-4. PubMed ID: 12039587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.
    Huang W; Naughton MA; Yang H; Su T; Dam S; Wong PW; Arfsten A; Edwards S; Sinha U; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):723-8. PubMed ID: 12639567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors.
    Wagner J; Kallen J; Ehrhardt C; Evenou JP; Wagner D
    J Med Chem; 1998 Sep; 41(19):3664-74. PubMed ID: 9733491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.
    Watson NS; Brown D; Campbell M; Chan C; Chaudry L; Convery MA; Fenwick R; Hamblin JN; Haslam C; Kelly HA; King NP; Kurtis CL; Leach AR; Manchee GR; Mason AM; Mitchell C; Patel C; Patel VK; Senger S; Shah GP; Weston HE; Whitworth C; Young RJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3784-8. PubMed ID: 16697194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in serine protease inhibitors as anticoagulant agents.
    Prezelj A; Anderluh PS; Peternel L; Urleb U
    Curr Pharm Des; 2007; 13(3):287-312. PubMed ID: 17313362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.
    Shi Y; Li C; O'Connor SP; Zhang J; Shi M; Bisaha SN; Wang Y; Sitkoff D; Pudzianowski AT; Huang C; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6882-9. PubMed ID: 19896847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally active zwitterionic factor Xa inhibitors with long duration of action.
    Mochizuki A; Nagata T; Kanno H; Takano D; Kishida M; Suzuki M; Ohta T
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7337-43. PubMed ID: 22044620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors.
    Su T; Yang H; Volkots D; Woolfrey J; Dam S; Wong P; Sinha U; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):729-32. PubMed ID: 12639568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.
    Jia ZJ; Wu Y; Huang W; Goldman E; Zhang P; Woolfrey J; Wong P; Huang B; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1651-5. PubMed ID: 12039583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY
    J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.